Literature DB >> 1926022

Comparison of the prevalence of reversible airways obstruction in rural and urban Zimbabwean children.

D J Keeley1, P Neill, S Gallivan.   

Abstract

The prevalence of reversible airways obstruction has been assessed in children in three areas in Zimbabwe--northern Harare (high socioeconomic class urban children), southern Harare (low socio-economic class urban children), and Wedza Communal Land (rural children from peasant families). Peak expiratory flow (PEF) was measured before and after six minutes' free running in 2055 Zimbabwean primary school children aged 7-9 years. Height and weight were measured and nutritional state expressed as a percentage of the 50th centile for age (Tanner-Whitehouse standards). Reversible airways obstruction was deemed to be present when peak expiratory flow was below the 2.5th centile for height before exercise and rose by more than 15% after inhalation of salbutamol and when it fell by 15% or more after exercise and rose again after salbutamol. The prevalence of reversible airways obstruction was 5.8% (95% confidence interval 4.1-7.5%) in northern Harare (n = 726); 3.1% (1.8-4.5%) in southern Harare (n = 642), and 0.1% (0.0-0.4%) in Wedza (n = 687). In northern Harare, the only study area in which white children were found, the prevalence of reversible airways obstruction was similar in white (5.3%, 10/188) and black (5.9%, 32/538) children. Indicators of nutritional state also showed no significant differences between white and black children in northern Harare but were lower in southern Harare and lower still in Wedza. Urban living and higher material standards of living appear to be associated with a higher prevalence of reversible airways obstruction in children in Zimbabwe.

Entities:  

Mesh:

Year:  1991        PMID: 1926022      PMCID: PMC463268          DOI: 10.1136/thx.46.8.549

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

1.  Asthma and IgE levels in rural and urban communities of The Gambia.

Authors:  R C Godfrey
Journal:  Clin Allergy       Date:  1975-06

2.  One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists.

Authors:  C P Page
Journal:  Lancet       Date:  1991-03-23       Impact factor: 79.321

3.  Exercise-induced asthma.

Authors:  S D Anderson; M Silverman; P König; S Godfrey
Journal:  Br J Dis Chest       Date:  1975-01

4.  Spirometry, lung volumes and airway resistance in normal children aged 5 to 18 years.

Authors:  S Godfrey; P L Kamburoff; J R Nairn
Journal:  Br J Dis Chest       Date:  1970-01

5.  A comparison of the effectiveness of free-running and treadmill exercise for assessing exercise-induced bronchospasm in clinical practice.

Authors:  G G Shapiro; W E Pierson; C T Furukawa; C W Bierman
Journal:  J Allergy Clin Immunol       Date:  1979-12       Impact factor: 10.793

6.  Asthma prevalence in Tokelauan children in two environments.

Authors:  D A Waite; E F Eyles; S L Tonkin; T V O'Donnell
Journal:  Clin Allergy       Date:  1980-01

7.  Prevalence of asthma: a comparative study of urban and rural Xhosa children.

Authors:  C H Van Niekerk; E G Weinberg; S C Shore; H V Heese; J Van Schalkwyk
Journal:  Clin Allergy       Date:  1979-07

8.  Prevalence of asthma and hay fever in England and Wales.

Authors:  D M Fleming; D L Crombie
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

9.  Prevalence and distribution of schistosomiasis in Zimbabwe.

Authors:  P Taylor; O Makura
Journal:  Ann Trop Med Parasitol       Date:  1985-06

10.  Seasonal asthma and the house-dust mite in tropical Africa.

Authors:  J B Cookson; G Makoni
Journal:  Clin Allergy       Date:  1975-12
View more
  33 in total

1.  Asthma and poverty.

Authors:  R J Rona
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

Review 2.  Prevalence of exercise induced bronchospasm in Kenyan school children: an urban-rural comparison.

Authors:  L W Ng'ang'a; J A Odhiambo; M W Mungai; C M Gicheha; P Nderitu; B Maingi; P T Macklem; M R Becklake
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

3.  Prevalence of asthma and respiratory symptoms in south-central Durban, South Africa.

Authors:  J Nriagu; T Robins; L Gary; G Liggans; R Davila; K Supuwood; C Harvey; C C Jinabhai; R Naidoo
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

4.  Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys.

Authors:  J V West; C F Robertson; R Roberts; A Olinsky
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

5.  Allergy sensitization and asthma among 13-14 year old school children in Nigeria.

Authors:  O Oluwole; O G Arinola; G A Falade; M O Ige; G A Falusi; T Aderemi; D Huo; I O Olopade; C O Olopade
Journal:  Afr Health Sci       Date:  2013-03       Impact factor: 0.927

6.  Reactivity of allergy skin test in healthy volunteers.

Authors:  Phisit Supakthanasiri; Jettanong Klaewsongkram; Hiroshi Chantaphakul
Journal:  Singapore Med J       Date:  2014-01       Impact factor: 1.858

7.  Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren.

Authors:  E O Addo Yobo; A Custovic; S C Taggart; A P Asafo-Agyei; A Woodcock
Journal:  Thorax       Date:  1997-02       Impact factor: 9.139

8.  Rural health disparities in asthma care and outcomes.

Authors:  Robert S Valet; Tamara T Perry; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2009-02-23       Impact factor: 10.793

9.  Prevalence of asthma and risk factors among Chinese, Malay, and Indian adults in Singapore.

Authors:  T P Ng; K P Hui; W C Tan
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

10.  Skin prick test reactivity to common allergens among women in Entebbe, Uganda.

Authors:  Harriet Mpairwe; Lawrence Muhangi; Juliet Ndibazza; Josephine Tumusiime; Moses Muwanga; Laura C Rodrigues; Alison M Elliott
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-03-05       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.